Clinical Microbiology and Antimicrobial Chemotherapy. 2020; 22(2):88-91
Objective. To assess efficacy and safety of methylprednisolone pulse therapy in patients with COVID-19.
Materials and Methods. A retrospective analysis of 57 patients with moderate and severe novel coronavirus infection (COVID-19) receiving methylprednisolone pulse therapy (500 mg/day IV for 2–3 consecutive days) was performed. Pre- and post-therapy examination of the patients included clinical (severity and duration of fever, gas exchange parameters), imaging (computed tomography) and laboratory tests (including C-reactive protein, procalcitonin, D-dimer).